As the focus on maintaining a low COVID-19 infection rate in our communities remains a priority, Ontario has made third doses of the COVID-19 vaccines available to additional vulnerable populations.
For those listed below, third doses are offered at least 6 months since their last dose:
As of November 6, 2021, individuals eligible for a booster vaccine dose have multiple options of booking a vaccination appointment. The options are listed below:
*If you are unsure of which public health unit is associated with your community, you can visit the following website to help you in your search: https://www.phdapps.health.gov.on.ca/phulocator/
For those eligible for a COVID-19 booster dose in Ontario, it is also recommended to get the flu shot at or around the same time.
Additionally, Ontario’s Ministry of Health has made the following recommendations regarding COVID-19 booster vaccine doses:
*These recommendations are based on the National Advisory Committee’s Interim Guidance on booster COVID-19 vaccine doses: (https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/statement-guidance-booster-doses/statement-guidance-booster-doses.pdf)
Kunal Bhatt, RPh, PharmD, HBSc is a staff pharmacist for Charlton Health. As a 2020 PharmD graduate from the University of Toronto, Kunal possesses a diverse range of experiences from working in hospital and community pharmacy settings. Since January 2021, Kunal was heavily invested in contributing to the efforts against COVID-19 by administering upwards of 5000 COVID-19 vaccines at William Osler Health System’s vaccination clinics.
Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.
Saphnelo (anifrolumab) is a one-of-a-kind therapy by AstraZeneca for the treatment of moderate to severe…
On December 4, 2023, Health Canada approved Pfizer’s Litfulo (ritlecitinib). Litfulo is a once-daily oral…
Infliximab is a protein-based medication referred to as a biologic that treats many immune-mediated conditions. …
On October 3rd, 2023, Health Canada approved Eli Lilly’s newest biologic for the treatment of…
As February is heart month, today is an excellent occasion to really show why we love our hearts and…
To better serve our Hamilton and area patients, we have expanded and moved our Stoney…